Metraipolis › archive › dc_eaef0686d877

Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects — Europe PMC PMID:42377444

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42377444
DOI: 10.1007/s00259-[numero omesso]-9
License (as archived): solo-consultazione
Archived: 2026-10-18T14:20:31.974Z
SHA-256 of the archived text: ac201db641d4f267cf39fa76ef2247e580538ba3c5357970d33bd06774c11392
Stable URL of this page: https://metraipolis.com/documento/dc_eaef0686d877

How to cite

Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects — Europe PMC PMID:42377444 — Europe PMC (en), https://europepmc.org/article/MED/42377444 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eaef0686d877 (Metraipolis archive dc_eaef0686d877, sha256 ac201db641d4f267cf39fa76ef2247e580538ba3c5357970d33bd06774c11392)

BibTeX

@misc{dceaef0686d877,
  title = {Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects — Europe PMC PMID:42377444},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42377444},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eaef0686d877; sha256 ac201db641d4f267cf39fa76ef2247e580538ba3c5357970d33bd06774c11392},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42377444. Agents can read the archived copy with the MCP tool read_document.